Company Overview - NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases [3] - The company is developing DA-1726 for obesity treatment and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [3] Product Development - DA-1726 is a novel oxyntomodulin (OXM) analogue that acts as a dual agonist for glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), potentially leading to superior weight loss compared to selective GLP1R agonists [3] - DA-1241 is a G-protein-coupled receptor 119 (GPR119) agonist that enhances the release of gut peptides GLP-1, GIP, and PYY, showing positive effects on liver inflammation, lipid metabolism, weight loss, and glucose metabolism in preclinical studies [3] Upcoming Events - NeuroBo management will present a company overview at the Emerging Growth Conference on July 18, 2024, at 10:50 am ET [1] - Following the presentation, there will be a Q&A session where questions can be submitted in advance [2][6]

Core Insights - NeuroBo Pharmaceuticals is advancing the clinical development of DA-1726, a dual agonist for GLP-1 and glucagon receptors, aimed at treating obesity, with top-line data expected in Q3 2024 for Part 1 and Q1 2025 for Part 2 of the Phase 1 trial [1][9] - Recent financing of up to $70 million will support ongoing clinical trials, including a planned Part 3 to assess total weight loss and dietary changes, with interim data expected in mid-2026 [1][10] Company Overview - NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [13] - DA-1726 is designed to be administered once weekly subcutaneously and has shown superior weight loss in pre-clinical models compared to existing treatments like semaglutide and tirzepatide [12][13] Clinical Trial Details - The Phase 1 trial consists of two parts: Part 1 (Single Ascending Dose) and Part 2 (Multiple Ascending Dose), with approximately 45 participants in Part 1 and 36 in Part 2, randomized to receive either DA-1726 or placebo [17] - Primary endpoints focus on safety and tolerability, while secondary endpoints will assess pharmacokinetics and exploratory endpoints will evaluate metabolic and cardiac parameters [2][17]

H.C. Wainwright & Co. acted as the exclusive placement agent for the offerings. The shares of common stock offered in the registered direct offering (but excluding the securities offered in the private placement and the shares of common stock underlying the warrants issued in the private placement) were offered and sold by NeuroBo pursuant to a "shelf" registration statement on Form S-3 (Registration No. 333-278646), including a base prospectus, previously filed with the Securities and Exchange Commission ( ...

Company Overview - NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases [3] - The company is developing DA-1726 for obesity treatment and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [3] - DA-1726 is a novel oxyntomodulin analogue acting as a GLP1R and GCGR dual agonist, potentially offering superior weight loss compared to selective GLP1R agonists [3] - DA-1241 is a GPR119 agonist that promotes release of gut peptides GLP-1, GIP, and PYY, showing positive effects on liver inflammation, lipid metabolism, and glucose control in preclinical studies [3] Financing Activities - The company entered into definitive agreements for private placement of 4,325,701 shares at $3.93 per share [6] - A concurrent registered direct offering involves 763,359 shares at the same price [6] - The offerings include Series A warrants for 5,089,060 shares and Series B warrants for 7,633,591 shares, both exercisable at $3.93 per share [6] - Aggregate gross proceeds expected to be approximately $20 million upfront, with potential additional $50 million if all warrants are exercised [11][16] - Proceeds will be used for working capital, general corporate purposes, and clinical development of DA-1726 [11] Clinical Development - Series A warrants expire upon positive Phase 1 MAD data readout for DA-1726 or 12 months after stockholder approval [6] - Series B warrants expire upon positive Phase 1 Part 3 data readout for DA-1726 or 5 years after stockholder approval [6] - The financing is expected to provide cash runway to complete Phase 1 Part 3 clinical trial of DA-1726 [16] Regulatory and Legal Aspects - The registered direct offering is made pursuant to a shelf registration statement (Form S-3, No. 333-278646) filed with SEC on April 12, 2024 and declared effective on April 23, 2024 [7] - The private placement and Series Warrants are made under Section 4(a)(2) of Securities Act and Rule 506(b) of Regulation D [18] - The company has agreed to file a registration statement with SEC covering resale of securities issued in private placement [18]

DA-1726 Also Exhibited Superior Glucose Lowering Compared to Survodutide Data Presented at the ADA 84th Scientific Sessions CAMBRIDGE, Mass., June 22, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced pre-clinical data which indicates that DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor ...

NeuroBo Pharmaceuticals, Inc. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37809 545 Concord Avenue, Suite 210 Cambridge, Massachusetts 02138 (Address of pri ...

Exhibit 99.1 NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Dosed First Patient in the Single Ascending Dose Part 1 of the Phase 1 Clinical Trial of DA-1726 in Obesity, With Top-Line Data Readout Expected in the Third Quarter of 2024 Anticipate First Patient to be Dosed in the Multiple Ascending Dose Part 2 of the Phase 1 Clinical Trial of DA-1726 in the Third Quarter of 2024 Part 2 of the Phase 2a Trial of DA-1241 for the Treatment of MASH Underway After ...

Dosed First Patient in the Single Ascending Dose Part 1 of the Phase 1 Clinical Trial of DA-1726 in Obesity, With Top-Line Data Readout Expected in the Third Quarter of 2024 Anticipate First Patient to be Dosed in the Multiple Ascending Dose Part 2 of the Phase 1 Clinical Trial of DA-1726 in the Third Quarter of 2024 Part 2 of the Phase 2a Trial of DA-1241 for the Treatment of MASH Underway After Enrollment of Part 1 Completed, With Data Expected in the Fourth Quarter of 2024 Cash of $16.0 Million, Expected ...

CAMBRIDGE, Mass., April 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced the acceptance of poster presentations for its promising cardiometabolic assets, DA-1241 and DA-1726, at the EASL Congress 2024 and the American Diabetes Association (ADA) 84th Scientific Sessions in June. "Having multiple posters selected for presentation at two of the most esteemed scientific forums ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37809 NeuroBo Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 47-2389984 (State or ...